EUVIMEDEUVIMED entdecken
LeserbriefFallbericht

Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin

Layla Veleanu, Laurence Lamant, David Sibon iD, Therapeutic Strategy Project for Adult ALK+ ALCL

New England Journal of Medicine · 2024

DOI: 10.1056/nejmc2402419 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Layla Veleanu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institut Necker Enfants Malades, Paris, France. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Antineoplastic Agents, Brentuximab Vedotin, Lymphoma, Large-Cell, Anaplastic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anaplastic Lymphoma KinaseAntineoplastic AgentsBrentuximab VedotinLymphoma, Large-Cell, AnaplasticAdultFemaleHumansMaleMiddle AgedImmunoconjugatesOrganophosphorus CompoundsProtein Kinase InhibitorsPyrimidinesTreatment Failure

Substanzen

ALK protein, humanAnaplastic Lymphoma KinaseAntineoplastic AgentsBrentuximab VedotinbrigatinibImmunoconjugatesOrganophosphorus CompoundsProtein Kinase InhibitorsPyrimidines

Autor:innen und Institutionen

  • Institut Necker Enfants Malades, Paris, France.
  • Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
  • Henri Mondor University Hospital, Créteil, France david.sibon@aphp.fr.

ORCID-Profile: David Sibon

Zitieren

APA

Veleanu, L., Lamant, L., Sibon, D., & Therapeutic Strategy Project for Adult ALK+ ALCL (2024). Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin. New England Journal of Medicine. https://doi.org/10.1056/nejmc2402419

Vancouver

Veleanu L, Lamant L, Sibon D, Therapeutic Strategy Project for Adult ALK+ ALCL. Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin. New England Journal of Medicine. 2024. doi:10.1056/nejmc2402419

BibTeX
@article{Veleanu2024,
  author = {Veleanu, Layla and Lamant, Laurence and Sibon, David and Therapeutic Strategy Project for Adult ALK+ ALCL, Therapeutic Strategy Project for Adult ALK+ ALCL},
  title = {Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejmc2402419}
}
Kostenlos starten →